ArticleTranslational cancer research2025
TIPE3 promotes breast cancer progression and metastasis via the AKT-GSK3β-β-catenin/Snail pathway.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The tumor necrosis factor-α-induced protein 8-like 3 (TNFAIP8L3, TIPE3) plays a critical role in phosphoinositide transport and metabolism to facilitate PI3K-AKT signaling activation. Elevated TIPE3 expression has been observed in multiple malignancies, including esophageal, cervical, colon, and lung cancers, suggesting its potential oncogenic role in tumor progression. However, the precise molecular mechanisms by which TIPE3 regulates breast cancer progression remain largely unclear. This study aims to investigate the role of TIPE3 in breast cancer cell growth and metastasis. Methods: TIPE3 expression in 100 paired breast cancer and adjacent tissues was analyzed via immunohistochemistry. Quantitative real-time polymerase chain reaction (qRT-PCR) and western blot assessed TIPE3 levels in breast cancer cell lines (MCF7, SKBR3, MDA-MB-231, MDA-MB-468) and normal mammary epithelial cell (MCF10A). TIPE3 overexpression and TIPE3 knockdown lentiviral constructs were generated and transfected into MCF7 and MDA-MB-231 cells. Functional assays, including Cell Counting Kit-8 (CCK-8), colony formation, cell cycle analysis, wound healing, and transwell invasion assays, evaluated proliferation, migration, and invasion. Tumor growth and metastasis were assessed in BALB/c nude mice. Western blot, qRT-PCR, and IHC examined the impact of TIPE3 on AKT-GSK3β-β-catenin/Snail signaling and epithelial-mesenchymal transition (EMT) marker expression. Results: TIPE3 expression was significantly upregulated in breast cancer tissues and cell lines. Stable TIPE3 overexpression (MCF7-TIPE3) and TIPE3 knockdown (MDA-MB-231-shTIPE3) cell lines were established. TIPE3 overexpression promoted proliferation, G1/S transition, migration, and invasion, whereas TIPE3 knockdown inhibited these processes and suppressed tumor growth and lung metastasis in nude mice. TIPE3 regulated the AKT-GSK3β-β-catenin/Snail signaling pathway, enhancing EMT marker expression while downregulating E-cadherin. Conclusions: TIPE3 expression is elevated in breast cancer and likely promotes breast cancer growth and metastasis through the AKT-GSK3β-β-catenin/Snail pathway. TIPE3 may be a novel therapeutic target for breast cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.